Literature DB >> 21130685

Infection Probability Score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy.

Eleni Apostolopoulou1, Vasilios Raftopoulos, Konstantinos Terzis, Ioannis Elefsiniotis.   

Abstract

PURPOSE: to assess the predictive power of three systems: Infection Probability Score, APACHE II and KARNOFSKY score for the onset of Clostridium difficile-associated disease (CDAD) in hematology-oncology patients. METHODS AND SAMPLE: A retrospective pilot surveillance survey was conducted in the hematology unit of a general hospital in Greece. Data were collected by using an anonymous standardised case-record form. The sample consisted of 102 hospitalized patients.
RESULTS: The majority of the patients (33.3%) suffered from acute myeloid leukemia. The cumulative incidence of CDAD was 10.8% and the incidence rate of C difficile associated diarrhea was 5 per 1000 patient-days (14.2 per 1000 patient-days at risk). Patients with CDAD had twofold higher time of mean length of hospital stay compared with patients without CDAD (38.82 ± 23.88 vs 19.45 ± 14.56 days). Additionally patients with CDAD had received a greater number of different antibiotics compared to those without CDAD (5.18 ± 1.99 vs 2.54 ± 2.13), suffered from diabetes, from non Hodgkin's lymphoma, had a statistically significant higher duration of neutropenia ≥3 days and had received antifungal treatment. The best cutoff value of IPS for the prediction of CDAD was 13 with a sensitivity of 45.5% and a specificity of 82.4%.
CONCLUSIONS: IPS is an early diagnostic test for CDAD detection. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21130685     DOI: 10.1016/j.ejon.2010.11.002

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  7 in total

1.  Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy.

Authors:  Young Kyung Yoon; Min Ja Kim; Jang Wook Sohn; Hye Suk Kim; Yoon Ji Choi; Jung Sun Kim; Seung Tae Kim; Kyong Hwa Park; Seok Jin Kim; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Yong Park
Journal:  Support Care Cancer       Date:  2014-03-05       Impact factor: 3.603

2.  Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan.

Authors:  Yuan-Pin Hung; Pei-Jane Tsai; Kuei-Hsiang Hung; Hsiu-Chuan Liu; Chih-I Lee; Hsiao-Ju Lin; Yi-Hui Wu; Jiunn-Jong Wu; Wen-Chien Ko
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

3.  Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals.

Authors:  Andrew Delgado; Ivan A Reveles; Felicia T Cabello; Kelly R Reveles
Journal:  BMC Infect Dis       Date:  2017-06-23       Impact factor: 3.090

4.  Pancreatic disease patients are at higher risk for Clostridium difficile infection compared to those with other co-morbidities.

Authors:  Chetana Vaishnavi; Pramod K Gupta; Megha Sharma; Rakesh Kochhar
Journal:  Gut Pathog       Date:  2019-04-23       Impact factor: 4.181

5.  Determining the risk factors associated with the development of Clostridium difficile infection in patients with hematological diseases.

Authors:  Yu Ling Lee-Tsai; Rodrigo Luna-Santiago; Roberta Demichelis-Gómez; Alfredo Ponce-de-León; Eric Ochoa-Hein; Karla María Tamez-Torres; María T Bourlon; Christianne Bourlon
Journal:  Blood Res       Date:  2019-06-25

6.  Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer.

Authors:  Anat Stern; Elena Carrara; Roni Bitterman; Dafna Yahav; Leonard Leibovici; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2019-01-03

7.  Clostridium difficile Infections amongst Patients with Haematological Malignancies: A Data Linkage Study.

Authors:  Linda A Selvey; Claudia Slimings; David J L Joske; Thomas V Riley
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.